Development_of_systemic_lupus_erythematosus_after_interferon_therapy_for_chronic_myelogenous_leukemia._A_19-year-old_man_with_Philadelphia-positive_chronic_myelogenous_leukemia_treated_with_interferon-alpha_(IFN-alpha)_therapy_for_45_months_had_systemic_lupus_erythematosus_disease_features:_malar_rash,_migratory_arthralgias,_elevated_antinuclear_antibodies,_elevated_antinative_DNA,_hypocomplementemia,_lymphopenia,_and_proteinuria._After_discontinuation_of_the_IFN_and_initiation_of_corticosteroids,_there_was_gradual_recovery_of_symptoms,_a_decline_in_antinative_DNA_and_antinuclear_antibodies_to_normal_levels,_and_a_decrease_in_proteinuria._The_potential_association_between_IFN_therapy_and_the_development_of_systemic_lupus_erythematosus,_and_the_role_of_IFN_in_other_autoimmune_diseases,_is_discussed.